1117 related articles for article (PubMed ID: 27242349)
1. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
2. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
4. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.
Cooley L; Dendle C; Wolf J; Teh BW; Chen SC; Boutlis C; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1350-63. PubMed ID: 25482745
[TBL] [Abstract][Full Text] [Related]
5. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
6. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK; Foisy MM; Hughes CA
Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
[TBL] [Abstract][Full Text] [Related]
7. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
[TBL] [Abstract][Full Text] [Related]
9. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
[TBL] [Abstract][Full Text] [Related]
10. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
[TBL] [Abstract][Full Text] [Related]
11. Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review.
Grewal P; Brassard A
J Cutan Med Surg; 2009; 13(6):308-12. PubMed ID: 19919808
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation.
Brakemeier S; Pfau A; Zukunft B; Budde K; Nickel P
Pharmacol Res; 2018 Aug; 134():61-67. PubMed ID: 29890253
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Risk Factors for Pneumocystis Jirovecii Pneumonia during Immunosuppressive Treatment in Patients with Ulcerative Colitis: A Retrospective Study.
Kojima K; Sato T; Uchino M; Yokoyama Y; Takagawa T; Ohda Y; Hida N; Watanabe K; Hori K; Miwa H; Ikeuchi H; Nakamura S; Shimizu M
J Gastrointestin Liver Dis; 2020 Jun; 29(2):167-173. PubMed ID: 32530983
[TBL] [Abstract][Full Text] [Related]
15. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
16. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients.
Roux A; Gonzalez F; Roux M; Mehrad M; Menotti J; Zahar JR; Tadros VX; Azoulay E; Brillet PY; Vincent F;
Med Mal Infect; 2014 May; 44(5):185-98. PubMed ID: 24630595
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
Ghembaza A; Vautier M; Cacoub P; Pourcher V; Saadoun D
Chest; 2020 Dec; 158(6):2323-2332. PubMed ID: 32502592
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Evaluation of Risk Factors for Pneumocystis jirovecii Pneumonia in Adult Solid Organ Transplant Recipients: A Systematic Review and Meta-analysis.
Permpalung N; Kittipibul V; Mekraksakit P; Rattanawong P; Nematollahi S; Zhang SX; Steinke SM
Transplantation; 2021 Oct; 105(10):2291-2306. PubMed ID: 33323766
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.
Basiaga ML; Ross ME; Gerber JS; Ogdie A
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):283-289. PubMed ID: 28992298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
